Drug Trial Radar · NCT04246359
Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Apr 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
52
Planned (sponsor's estimate)
Start
Jan 15, 2020
Primary completion
Jun 16, 2022
Study completion Jan 16, 2023
Sponsor
- Lead sponsor
- Huiqiang HuangAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 29, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 2 open label study to evaluate safety and activity of Rituximab(HLX01) in combination with Pegylated interferon α-2b in patients with newly diagnosed advanced indolent B-cell lymphoma.
Conditions
- Lymphoma, B-Cell
Interventions
Rituximab BiosimilarDrug
To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.
Pegylated Interferon α-2bDrug
To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)、Complete Remission Rate (CRR)、Partial Remission Rate (PRR)Time frame: Up to 21 weeks
- HBsAg clearance rate and anti-Hbs antibody positive rate in patients with chronic hepatitis B at 72 weeksTime frame: Up to 72 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Medical Oncology, Sun Yat-sen University Cancer Center,
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.